Abstract | BACKGROUND: METHODS: We retrospectively reviewed 46 courses of radiotherapy administered to 15 consecutive patients with adult T-cell leukaemia/ lymphoma (acute, n = 7; lymphoma, n = 7; smouldering, n = 1) who received mogamulizumab before or during radiotherapy at three institutions between 2012 and 2017. RESULTS: CONCLUSION:
|
Authors | Hitoshi Maemoto, Takuro Ariga, Takeaki Kusada, Joichi Heianna, Yoshihiko Manabe, Akifumi Miyakawa, Sawako Nakachi, Satoko Morishima, Shiro Iraha, Fumikiyo Ganaha, Hiroaki Masuzaki, Sadayuki Murayama |
Journal | Japanese journal of clinical oncology
(Jpn J Clin Oncol)
Vol. 49
Issue 2
Pg. 153-159
(Feb 01 2019)
ISSN: 1465-3621 [Electronic] England |
PMID | 30452692
(Publication Type: Journal Article, Multicenter Study)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- mogamulizumab
|
Topics |
- Adult
- Aged
- Antibodies, Monoclonal, Humanized
(administration & dosage, adverse effects, therapeutic use)
- Female
- Humans
- Leukemia-Lymphoma, Adult T-Cell
(drug therapy, radiotherapy)
- Male
- Middle Aged
- Radiodermatitis
(chemically induced, diagnostic imaging)
- Retrospective Studies
- Skin
(pathology, radiation effects)
- Survival Analysis
|